Altimmune announced 48-week data from its IMPACT Phase 2b trial showing that pemvidutide, a glucagon/GLP-1 dual receptor agonist, significantly reduced triglycerides (-23.7%), total cholesterol (-15.4%), and improved weight loss (7.5%), blood pressure, and waist circumference in MASH patients. The drug demonstrated a favorable safety profile with minimal discontinuations due to adverse events. The company plans to initiate the PERFORMA Phase 3 trial in the second half of 2026.

Altimmune closed a $225 million oversubscribed public offering led by Deep Track Capital, with participation from TCGX, Viking Global Investors, and RA Capital Management. The company will use proceeds to fund its Phase 3 MASH trial expected to initiate in H2 2026 and provide cash runway through the anticipated 52-week data readout. Pemvidutide, Altimmune's dual-action therapy targeting glucagon and GLP-1 receptors, is being developed for MASH, alcohol use disorder, and alcohol-associated liver disease.

Altimmune, Inc. (Nasdaq: ALT) announced the pricing of an underwritten public offering of common stock and warrants expected to raise approximately $225 million in gross proceeds. The offering consists of 64.25 million shares of common stock with accompanying warrants at $3.00 per share, plus optional pre-funded warrants. The company plans to use net proceeds to fund its Phase 3 MASH trial and general corporate purposes. The offering is expected to close on April 24, 2026.

Avaí Bio announced a critical milestone in creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, an anti-aging protein that declines by 50% after age 40. The company is partnering with Austrianova to use Cell-in-a-Box encapsulation technology for its Klothonova anti-aging and Insulinova diabetes programs. This development occurs as the cell and gene therapy market expands rapidly, with the sector forecast to grow from $10.4 billion to over $45 billion by 2035.

Altimmune Inc (NASDAQ: ALT) closed a $75 million registered direct offering of common stock, issuing 17,045,454 shares to a new fundamental institutional investor. The company plans to use the net proceeds for its Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and general corporate purposes. The offering strengthens Altimmune's balance sheet as it advances its lead candidate pemvidutide, a dual glucagon/GLP-1 agonist that received FDA Breakthrough Therapy Designation.

Altimmune, Inc. closed a $75 million registered direct offering of common stock and pre-funded warrants to strengthen its balance sheet. The company plans to use proceeds for its Phase 3 trial of pemvidutide, a dual glucagon/GLP-1 agonist for MASH treatment, which recently received FDA Breakthrough Therapy Designation.

The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.

Altimmune, Inc. announced a registered direct offering of approximately 17 million shares to raise $75 million in gross proceeds. The company plans to use the funds to prepare for its Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) using its lead candidate pemvidutide, a glucagon/GLP-1 dual agonist that recently received FDA Breakthrough Therapy Designation and demonstrated positive Phase 2b results.

The global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.

Faruqi & Faruqi is investigating potential claims against Altimmune after its stock price dropped 53.2% following disappointing Phase 2b MASH trial results for Pemvidutide, where statistical significance was not achieved.

A class action lawsuit has been filed against Altimmune, alleging the company made false and misleading statements about its Pemvidutide trial results in the MASH Phase 2b study, with claims of overstated efficacy and downplaying of statistical significance.

Rosen Law Firm alerts Altimmune investors about a securities class action lawsuit regarding misleading information about the IMPACT Phase 2b MASH trial results, with an October 6, 2025 deadline to join the action.